Hanwei Yin Selected Research

Thioredoxin-Disulfide Reductase

4/2022	Quantification of the major circulating metabolite of BS1801, an ebselen analog, in human plasma.
1/2021	Therapeutic Effects of an Inhibitor of Thioredoxin Reductase on Liver Fibrosis by Inhibiting the Transforming Growth Factor-β1/Smads Pathway.
1/2021	Clinical application of thioredoxin reductase as a novel biomarker in liver cancer.
10/2020	Author Correction: Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer.
12/2019	Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer.
1/2019	Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study.
9/2017	Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells.
1/2011	Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition: Simultaneous regulation of TrxR transcription, expression and enzyme activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hanwei Yin Research Topics

Disease

7	Neoplasms (Cancer) 01/2021 - 09/2010
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 05/2022 - 04/2022
2	Liver Cirrhosis (Hepatic Cirrhosis) 04/2022 - 01/2021
2	Liver Neoplasms (Liver Cancer) 01/2021 - 01/2018
2	Stomach Neoplasms (Stomach Cancer) 10/2020 - 12/2019
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 09/2017
1	Interstitial Lung Diseases (Interstitial Lung Disease) 04/2022
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Non-alcoholic Fatty Liver Disease 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2018
1	Necrosis 09/2017
1	Leiomyoma (Uterine Fibroids) 05/2013
1	Carcinogenesis 03/2012
1	Lung Neoplasms (Lung Cancer) 03/2012
1	Lactic Acidosis 09/2010
1	Hypoxia (Hypoxemia) 09/2010
1	Breast Neoplasms (Breast Cancer) 09/2010
1	Starvation 09/2010

Drug/Important Bio-Agent (IBA)

8	Thioredoxin-Disulfide ReductaseIBA 04/2022 - 01/2011
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2019
3	(1,2- bis(1,2- benzisoselenazolone- 3(2H)- ketone))ethaneIBA 09/2017 - 01/2011
2	butaselenIBA 05/2022 - 01/2021
2	SeleniumIBA 04/2022 - 01/2021
2	Pharmaceutical PreparationsIBA 01/2021 - 03/2012
1	ebselenIBA 05/2022
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021
1	AntioxidantsIBA 01/2021
1	CollagenIBA 01/2021
1	SilymarinIBA 01/2021
1	ThioredoxinsIBA 01/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Carcinoembryonic AntigenIBA 12/2019
1	AntigensIBA 12/2019
1	Sodium SeleniteIBA 09/2017
1	Selenious Acid (Selenite)IBA 09/2017
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 05/2013
1	Thioredoxin Reductase 1IBA 03/2012
1	EnzymesIBA 01/2011
1	Antineoplastic Agents (Antineoplastics)IBA 01/2011
1	EthaneIBA 01/2011
1	KetonesIBA 01/2011
1	Glucose (Dextrose)FDA LinkGeneric 09/2010

Therapy/Procedure

1	Oral Administration 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Intraperitoneal Injections 01/2021
1	Chemoprevention 01/2018